OPKO Health Inc OPK
News
OPKO Health’s OPKO Biologics Doses First Participant in Phase 1/2a Trial of OPK-8801001 for Acromegaly
Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health
OPKO Health to Participate in the Wells Fargo 21st Annual Healthcare Conference
OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests
Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health

